Marrow raises $173M to develop siRNA alternative to gene therapy for sickle cell
Startup Marrow Therapeutics raised $173 million to develop an siRNA-based infusion therapy for sickle cell disease and beta thalassemia, positioning it as a more accessible alternative to approved one-time CRISPR and gene therapy treatments.